Skip to main content

Abbvie Inc(ABBV-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada - Thu Feb 8, 7:00AM CST

MONTREAL, Feb. 8, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that VYALEV (foslevodopa/foscarbidopa solution) is now available for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson's medicinal products.3


Provided Content: Content provided by The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald